Impax Laboratories (NASDAQ: IPXL) and SciClone Pharmaceuticals (NASDAQ:SCLN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Risk & Volatility

Impax Laboratories has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500. Comparatively, SciClone Pharmaceuticals has a beta of 1.72, meaning that its stock price is 72% more volatile than the S&P 500.

Institutional & Insider Ownership

86.3% of Impax Laboratories shares are held by institutional investors. Comparatively, 72.8% of SciClone Pharmaceuticals shares are held by institutional investors. 3.2% of Impax Laboratories shares are held by insiders. Comparatively, 5.2% of SciClone Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Impax Laboratories and SciClone Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Impax Laboratories -71.08% 9.05% 3.20%
SciClone Pharmaceuticals 25.18% 21.10% 19.03%

Analyst Ratings

This is a summary of current ratings and price targets for Impax Laboratories and SciClone Pharmaceuticals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Impax Laboratories 1 9 5 0 2.27
SciClone Pharmaceuticals 0 1 0 0 2.00

Impax Laboratories currently has a consensus target price of $19.67, suggesting a potential downside of 5.22%. SciClone Pharmaceuticals has a consensus target price of $14.00, suggesting a potential upside of 25.56%. Given SciClone Pharmaceuticals’ higher possible upside, analysts plainly believe SciClone Pharmaceuticals is more favorable than Impax Laboratories.

Valuation and Earnings

This table compares Impax Laboratories and SciClone Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Impax Laboratories $812.82 million 1.83 $144.42 million ($8.07) -2.57
SciClone Pharmaceuticals $172.02 million 3.38 $45.42 million $0.82 13.60

Impax Laboratories has higher revenue and earnings than SciClone Pharmaceuticals. Impax Laboratories is trading at a lower price-to-earnings ratio than SciClone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

SciClone Pharmaceuticals beats Impax Laboratories on 8 of the 13 factors compared between the two stocks.

Impax Laboratories Company Profile

Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma. The Impax Generics segment is focused on the development, manufacture, sale and distribution of its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma segment is engaged in the promotion, sale and distribution of several branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson’s disease, post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.

SciClone Pharmaceuticals Company Profile

SciClone Pharmaceuticals, Inc. is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Company’s lead product ZADAXIN (thymalfasin) is approved in over 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, SciClone markets seven partnered and in-licensed products in China. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL). Its development portfolio includes Angiomax, Loramyc, Neucardin, VIBATIV and Cleviprex.

Receive News & Ratings for Impax Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.